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There have been a number of agents that have been tried for treatment of gastroparesis over the past 3 
decades, with varying levels of success. Guidelines exist for the management of gastroparesis in adults; 
however, even though the cause of gastroparesis in children is similar to that in adults, no guidelines exist 
for treating pediatric gastroparesis as studies on the topic are limited. With what little information we have 
on pediatric gastroparesis, medications used in children’s studies do not seem to demonstrate the same 
results as in adult patients with gastroparesis; thus, future studies of whether certain medications are effec-
tive for treating pediatric gastroparesis and at what dose still need to be conducted. Pharmacological treat-
ment options for pediatric gastroparesis do not show a clear correlation of resolving or even maintaining 
gastroparesis-associated symptoms or disease state. This article reviews the available studies of drugs that 
have shown some efficacy, with an emphasis on pediatric studies.
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INTRODUCTION
Gastroparesis is a debilitating disease that can 
present with a constellation of symptoms includ-
ing nausea, vomiting, early satiety, anorexia, 
weight loss, and epigastric pain. Gastroparesis 
is defined as the impaired transit of intraluminal 
contents from the stomach to the duodenum in 
the absence of mechanical obstruction. Diagnosis 
of gastroparesis is based on the presentation of 
gastroparesis-associated symptoms that exist 
without any gastric outlet obstruction or ulcer-
ation and delayed gastric emptying.1 Delayed 
gastric emptying is the key diagnostic symptom 
of gastroparesis resulting from paresis of the 
stomach, causing its contents to remain in the 
stomach for a prolonged period of time. Com-
plications associated with gastroparesis may 
include Mallory-Weiss tears from repeated vom-
iting, bezoar formation, malnutrition, aspiration 
pneumonia, and electrolyte disorders.2
It may be difficult to assess the cause of gastro-
paresis, because most adult cases are idiopathic 
in nature.3 Presentation of gastroparesis in the 
pediatric population is seen largely after viral 
infection or surgical interventions. Patients with 
long-standing diabetes may be at increased risk 
of developing gastroparesis due to the develop-
ment of neuropathies and alterations in vagal 
innervation.4 Additionally, gastric motility may 
be impaired secondary to intestinal surgery, viral 
infections, neurologic disorders, psychological 
distress, anticholinergic agents, and overuse of 
opioids.2 In general, idiopathic disease tends to 
be more severe and persistent, whereas post-
infectious gastroparesis is self-limiting and may 
resolve over several months.5
Clinical guidelines for management of gastro-
paresis in adults recommend restoring fluids and 
electrolytes in patients and providing nutritional 
support, preferably through oral intake. Phar-
macologic therapy is used in conjunction with 
dietary therapy in attempts to improve gastric 
emptying and gastroparesis-associated symp-
toms. Prokinetic medications are most often the 
first line pharmacological treatment, which work 
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by increasing gastrointestinal motility; liquid 
formulation of metoclopramide prescribed at the 
lowest effective dose is the drug of choice.1 In pa-
tients who do not respond to prokinetic therapy, 
other pharmacologic recommendations include 
intravenous erythromycin to improve gastric 
emptying, antiemetics agents for alleviating as-
sociated symptoms of gastroparesis, or tricyclic 
antidepressants for managing refractory nausea 
and vomiting. Neither antiemetics nor tricyclic 
antidepressants improve gastric emptying time 
and thus are only conditionally recommended 
as pharmacologic treatment for gastroparesis 
in adults.1
Currently, there are no standardized clinical 
guidelines for treating gastroparesis in pediat-
rics. Similar to treatment for adult patients, the 
first-line recommendation is to restore fluid and 
electrolytes in the patient while establishing 
proper nutritional support and/or nutritional 
counseling. Pharmacologic recommendations 
are individualized and are intended to increase 
gastric emptying and manage associated symp-
toms to improve the patient’s lifestyle. Prokinetic 
therapy is preferred as the first-line medication 
therapy for gastroparesis as it accelerates intes-
tinal transit; however, studies of medications in 
this class suggest that they are not as effective in 
children as they are in adults. 
In addition to nutritional management and 
support, other non-pharmacological options ex-
ist for managing gastroparesis in both pediatrics 
and adults; however, this article reviewed and 
evaluated the current literature for the pharma-
cologic treatments of gastroparesis with a focus 
on pediatric studies where available.
METHODS
Databases PubMed (1975-2014) and Ovid 
MEDLINE (1975-2014) were searched using 
terms “gastroparesis,” “gastric emptying,” and 
“pediatrics” and combinations of these terms 
with each of the pharmacologic agents used to 
treat gastroparesis. Reference lists from all iden-
tified studies and reviews were also assessed 
for relevant papers. Initially, inclusion criteria 
were limited to pediatric studies; however, this 
approach yielded a small number of pediatric 
studies. Because adult studies are relevant to 
the pediatric population, inclusion criteria were 
expanded to include both primary and secondary 
articles on adult and pediatric pharmacotherapy 
for diseases of gastric dysmotility. Additionally, 
preclinical studies related to treatment of gastro-
paresis in pediatrics were included.
REVIEW OF LITERATURE
Metoclopramide
Metoclopramide (MCP) was approved by 
the U.S. Food and Drug Administration (FDA) 
in 1979 for gastroparesis and remains the first-
line agent for pharmacologic therapy. Favor-
able prokinetic effects are mediated through 
antagonism of the dopamine 2 (D2)-receptor to 
promote gastric emptying, as well as binding to 
the 5-hydroxytryptamine receptor 4 (serotonin 
5-HT4) to stimulate cholinergic neural pathways 
in the stomach.7 Physiologically, MCP accelerates 
intestinal transit by increasing the tone and am-
plitude of gastric contractions as well as relaxing 
the pyloric sphincter and the duodenal bulb.8 
Additionally, this agent provides antiemetic relief 
through antagonism of central and peripheral 
dopamine receptors.7
Several studies have compared placebo to 
MCP in with adult patients and found that 
MCP improved symptoms and gastric emptying 
time, assessed by radionuclide scintigraphy. 9-11 
Although prokinetic effects have been studied 
extensively in adults, studies supporting its 
use in pediatrics are sparse and suggests it 
may not be as effective. There is some evidence 
that the underlying cause of gastroparesis may 
determine the patient’s response to therapy. A 
randomized, controlled study performed by 
Hyman et al15 found that MCP is not efficacious 
in premature and neonatal populations whose 
primary cause of gastroparesis is prematurity. In 
light of previous studies linking the lack of effica-
cy in younger populations to a down-regulation 
in D2 receptors
12 and reduced responsiveness to 
prokinetic therapy in those with mitochondrial 
disorders,16 it may be reasonable to predict effec-
tiveness based on age. It has been hypothesized 
that lower D2 receptor expression in neonates 
may be the cause of its reduced effectiveness. 
Tube feedings that contained 0.2 mg/kg MCP 
had no effect on promoting gastric motility in 
low-birth-weight neonates but may be helpful in 
reducing emesis due to its actions on the chemo-
receptor trigger zone.12-14 The usefulness of MCP 
in neonates may be due to the centrally acting 
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antiemetic properties and not the pro-kinetic 
effects seen through binding of the D2 receptor 
in the peripheral nervous system. In preliminary 
animal studies, Kasirer et al12 found that neonatal 
rats that received MCP showed no differences in 
fundic muscle contraction upon induction with 
electrical field stimulation. In contrast, MCP was 
found to have statistically significant differences 
in electronic field stimulation-induced fundic 
muscle contraction in juvenile and adult rats. 
Additionally, the number of D2 receptors was 
significantly reduced in the neonatal rat gastric 
tissues, which may account for the lack of ef-
ficacy.12 Whether this result can be extrapolated 
to humans is the question.
A retrospective chart review from a single in-
stitution evaluated the effectiveness of prokinetic 
agents in 230 pediatric patients with gastropa-
resis.14 Similar to the effects in adult population, 
post-viral gastroparesis, defined as persistence 
of symptoms 1 month after onset of viral illness, 
was a dominant cause. Medication noted in the 
study included MCP, domperidone, tegaserod, 
erythromycin, proton pump inhibitors (PPIs), 
and cyproheptadine. The majority of patients 
(n = 173; 75%) received MCP as the promotil-
ity agent. Dosages ranged from 0.1 to 0.2 mg/
kg (maximum of 10 mg/dose) and were given 
4 times daily. Mean duration of treatment was 
8.6 months. Not only were 80% of patients non-
responsive to MCP therapy, but MCP was associ-
ated with the greatest number of adverse effects. 
Adverse effects such as, headaches, vomiting, 
behavioral changes, dystonia, movement dis-
orders, drowsiness, dizziness, and galactorrhea 
were reported by 34 patients (24%). Although a 
subgroup analysis evaluating efficacy of MCP 
based on age was not performed, a positive as-
sociation was noted between promotility agents 
in children (1-12 years of age) compared to that 
in adolescents and infants (p = 0.07).
Other factors affecting drug absorption and 
metabolism should be considered when consid-
ering an optimal medication regimen. The 2013 
adult guidelines for treatment of gastroparesis 
recommend oral liquid formulation of MCP 
over tablets due to its preferential absorption 
profile.1 In a recent article by Parkman et al,17 
the nasal spray formulation of MCP was pre-
ferred over oral tablets for symptom relief from 
gastroparesis.
Responses to therapy may also be predicted by 
pharmacogenomic testing. Polymorphisms in the 
KCNH2 and ADRA1D genes have been linked 
to better clinical response, whereas the CYP2D6, 
KCNH2, and HTR4 genes are associated with 
manifestation of adverse effects.18
Although MCP is the only FDA-approved 
treatment for gastroparesis, it is not a benign 
drug and its adverse effects ultimately limit its 
use. There is a “black box” warning for tardive 
dyskinesia that is associated with the duration 
of treatment and total cumulative dose. For this 
reason, use of MCP should be limited to 12 weeks 
unless therapeutic benefit is thought to outweigh 
the risk of developing a movement disorder that 
is often irreversible.8
Domperidone
Domperidone (DMP) exerts its prokinetic ef-
fects through antagonizing D2 receptors, which 
enhances antral-duodenal contraction and leads 
to improved peristalsis. DMP also has antiemetic 
properties through its effect on the chemorecep-
tor trigger zone found outside of the blood-brain 
barrier in the fourth ventricle. The benefit of 
using DMP over MCP is that it does not readily 
cross the blood-brain barrier, resulting in de-
creased central nervous system adverse effects. 
Compared to other prokinetic agents, DMP has 
no cholinergic activity.19
In a retrospective review by Rodriguez et al, 
33 children (out of 230 total pediatric patients) 
within the study were put on DMP after a failed 
trial of a first line agent (either a PPI or MCP). 
Dosage of DMP was 0.1 to 0.2mg/kg per dose 
given 4 times daily, with a maximum dose of 
10 mg 4 times daily for a mean duration of 
therapy of 7.6 months. Of 31 patients available for 
follow-up, 74% of patients taking DMP therapy 
responded compared to only 20% who were tak-
ing MCP and responded to treatement.14 In that 
study, DMP produced the highest resolution rate 
and caused the fewest adverse effects; with 6% 
of its patients reporting abdominal pain and/
or movement disorders as adverse effects. In 
another trial comparing 0.3 mg/kg DMP with 
placebo given 3 times a day to 22 preterm infants 
with gastric dysmotility, the mean gastric empty-
ing time for the treatment arm was significantly 
reduced: 47 minutes compared to the 68 minutes 
for the control.22
Adult studies have also shown that DMP 
compared to MCP appears to have a comparable 
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efficacy but possesses an improved adverse effect 
profile. A double-blind, multicenter, randomized 
trial of 93 adult subjects compared adverse effects 
and efficacy of 20 mg DMP to 10 mg MCP in dia-
betic gastroparesis. Efficacy was similar between 
the two groups in reducing the appearance and 
severity of symptoms such as nausea, vomiting, 
early satiety, and bloating/distention from base-
line. There was, however, a significantly greater 
reduction in mental acuity in MCP patients at 
four weeks, as well as non-significant increases 
in somnolence, akathisia, anxiety, and depression 
at two and four weeks.21
Despite that DMP has been shown to be an 
effective alternative to MCP in the treatment of 
gastroparesis, its use is not without risks. Oral 
DMP has been found to be associated with a 
mean QTc prolongation of 14 milliseconds in in-
fants at an advanced gestational age of ≥ 32 week 
of amenorrhea, and in those with a serum potas-
sium level at the upper limit of normal.23 The pro-
arrhythmic effect of DMP is such a concern that 
the FDA has not approved it for use in the United 
States, even outlawing acquisition through com-
pounding pharmacies.24 Physicians who would 
like to prescribe DMP for patients with severe 
gastroparesis or severe gastrointestinal motility 
disorders that are refractory to standard therapy 
may only obtain the drug through opening an 
Investigational New Drug Application.7
Although the use of DMP is currently limited, 
given the lack of a very good prokinetic alterna-
tive, DMP is a drug that could enjoy wider use in 
the future.25 Pharmacogenetic information about 
responders, for example, could in future give us 
an insight into how to best target therapy. Efficacy 
of therapy has been linked with the potassium 
channel gene KCNH2 and the drug transporter 
ABCB1. The adrenoreceptor gene ADRA1D, on 
the other hand, is thus far the only one associated 
with adverse effects.26
Cisapride
Cisapride promotes acetylcholine release in the 
myenteric plexus of the gut and indirectly stimu-
lates gastrointestinal motility. Cisapride acts as 
an agonist at 5-HT4 receptors and an antagonist 
at 5-HT3 receptors, both of which contribute to 
the release of acetylcholine and subsequent pro-
kinetic effects. It is also noteworthy that, unlike 
metoclopramide, cisapride is devoid of central 
nervous system effects because of its lack of 
antidopaminergic activity.27
Although cisapride was first approved by the 
FDA for treatment of nocturnal heartburn, it had 
at one time been the preferred agent for condi-
tions of gastric impairment due to promising 
in vitro and early clinical trial data.7,27 Evidence 
for its efficacy in adults, however, was and 
still is mixed. A few studies have reported that 
esophageal and gastric emptying of solid and 
liquid foods was much improved after both a 
single and repeated doses of cisapride.28,29 Other 
trials suggested that observed gastric emptying 
does not necessarily translate into symptom im-
provement.30,31 In some studies, cisapride simply 
failed to demonstrate a benefit in gastroparesis 
altogether.32 The disparity between the trials can 
possibly be accounted for by methodological 
variances and heterogeneity in the population 
studied; however, a clear conclusion still cannot 
be made.
Data for the pediatric population are even 
more limited, although what is available does 
not favor cisapride. In a trial of cisapride efficacy 
(0.2 mg/kg 3 times daily) in 10 preterm infants, 
the investigators found that cisapride might in 
fact delay gastric emptying, as the half gastric 
emptying time was significantly longer in the 
cisapride group. The whole gastrointestinal tran-
sit time was also longer in the cisapride group 
but not statistically different from that in the 
placebo group. Based on their results, the authors 
advised not using cisapride in preterm infants.33 
Compared to other prokinetic agents, cisapride 
also fared worse. In a randomized study of 28 
insulin-dependent children 6 to 16.9 years of 
age, cisapride (0.8 mg/kg) was compared with 
DMP (0.9 mg/kg). At the end of the 8-week pe-
riod, the DMP group had statistically significant 
improvements in symptoms as well as reduced 
gastric emptying time, normalized gastric electri-
cal activity, decreased prevalence of episodes of 
gastric dysrhythmias, and better glycemic control 
than the cisapride group.34
From a safety standpoint, cisapride initially 
was shown to have an acceptable adverse ef-
fect profile. In a comparison of 10,000 (adult) 
patients in a phase IV study, and 13,000 patients 
in a prescription event-monitoring program, the 
most common adverse events reported were di-
arrhea, headache, abdominal pain, constipation, 
and nausea.35 Later studies, however, suggested 
something different. In one such study, QTc 
Pharmacologic Treatment for Pediatric Gastroparesis
JPPT
124 J Pediatr Pharmacol Ther 2016 Vol. 21 No. 2 • www.jppt.org
prolongation was observed after 3 to 8 weeks of 
treatment in those children (6 months to 4 years 
of age) with underlying cardiac disease.36 In Janu-
ary of 2000, Janssen Pharmaceutica, Inc., warned 
physicians about the risks and contraindications 
related to cisapride. From 1993 to 2000, there 
had been 270 reported cases of serious cardiac 
arrhythmias such as ventricular tachycardia, 
ventricular fibrillation, torsades de pointes, and 
QTc prolongation in patients taking cisapride. 
Seventy of those reported cases resulted in fatali-
ties. The company also noted that in 85% of those 
cases the events occurred in patients with known 
risk factors, including concomitant use of QTc-
prolonging drugs, inhibition of CYP 3A4 enzyme, 
or depletion of serum electrolytes.37 Finally, on 
July 14, 2000, Janssen Pharmaceutica, Inc. an-
nounced it would stop marketing cisapride in 
the United States. The drug is now available only 
through a limited access program for patients 
who meet specific clinical eligibility criteria.7
Macrolide Antibiotics
Macrolide antibiotics at reduced antimicrobial 
dosages, such as erythromycin oral suspension 
at 50 to 100 mg 3 to 4 times daily and 30 to 45 
minutes prior to meals, promotes gastric motility 
and improves symptoms of early satiety, full-
ness, and vomiting.2 Unlike previous prokinetic 
agents, which act primarily on the D2 receptor, 
these agents act directly on motilin, which is an 
amino acid peptide synthesized in mucosal en-
docrine cells. Its name is derived from its ability 
to stimulate the motility of digestive organs.38 
Although the mechanism of action of motilin on 
gastric motility is not entirely understood, its 
activity on its endogenous receptor is believed to 
regulate phase III of the migrating motor complex 
(MMC), the presence of which is reflective of 
peristaltic activity in the antrum and duodenum. 
The MMC is the motor pattern present during 
the body’s fasting state, with the active phase III 
responsible for the clearing of debris and indi-
gestible material from the stomach and intestine 
into the colon.2
Erythromycin use in children seems not to 
have similar results, as a study demonstrated 
that erythromycin, 3 mg/kg given 4 times daily, 
up to 10 mg/kg 4 times daily, produced the low-
est resolution rate of gastroparesis symptoms 
in pediatrics with gastroparesis.14 A study of 
children (4 to 15 years of age) compared gastric 
residual volumes with premedication of either 
erythromycin (0.15 mg/kg) or metoclopramide 
(1 mg/kg) undergoing a tonsillectomy. The study 
demonstrated that there were no significant 
differences between gastric residual volumes, 
nor were there differences in postoperative nau-
sea and vomiting after pretreatment of either 
medication. Thus, erythromycin may be as ef-
fective as metoclopramide as a prokinetic agent 
and perhaps preferred due to its absence of the 
extrapyramidal adverse effects associated with 
metoclopramide.42
In the adult population, erythromycin has 
demonstrated both effectiveness (compared to 
placebo) and preferential use compared to other 
motility agents.39 A single blind, crossover adult 
study of 13 patients tested the efficacy of 250-
mg erythromycin compared to that of 10-mg 
MCP, both of which were given 3 times a day 
for the treatment of diabetic gastroparesis. Upon 
completion of the 3-week therapy, significant 
improvements in total scores of gastrointestinal 
symptoms were observed with both of the drugs, 
although the half-time of gastric emptying was 
more pronounced with erythromycin.38 Similarly, 
in a systematic analysis of 36 studies with 514 
adult patients, erythromycin was found to have 
the strongest effect on gastric emptying and im-
provement of symptoms than DMP, cisapride, 
or metoclopramide. Its availability and efficacy 
make erythromycin a welcome alternative to 
metoclopramide.41 Although studies show that 
erythromycin effectively treats gastroparesis in 
adults, studies in pediatrics patients demonstrate 
that one cannot extrapolate these notions and 
apply them in pediatric use.
Promising studies on erythromycin in regards 
to gastric motility in the pediatric population 
focus mainly on improving feeding tolerance in 
low-birth-weight and premature infants. Eryth-
romycin (15–30 mg/kg/day) is able to induce 
antral contractility, though its ability to produce 
propagated phase!! III MMC activity come with 
a major caveat.14, 43-44 Although non-propagating 
antral activity is present, indicating the presence 
of motilin receptors, it is not until 32 weeks that 
premature phase III MMC activity is observed.45-48 
Therefore, pre-term infants <32 weeks gestation 
might not benefit from erythromycin as much as 
their older counterparts.49-50
It might be possible to improve antroduodenal 
coordination using combination therapy with 
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erythromycin and another agent that induces 
phase III MMC. Sixteen symptomatic pediatric 
patients (mean age of 8.7 years) were studied 
in one such trial using adjunctive octreotide. 
Erythromycin was administered at 1 mg/kg in-
travenous infusion after 3 hours of fasting, and 
octreotide (0.5 mcg/kg) was given subcutane-
ously 1 hour after the erythromycin infusion. Ten 
patients had spontaneous phase III of the MMC 
without treatment medications, 12 had phase III 
after erythromycin, and 15 had phase III after 
octreotide, all of which originated in the antrum. 
Sequential use of erythromycin and octreotide in 
children may therefore be beneficial in treatment 
of gastric motility disorders, as the combination 
therapy was found to stimulate both antral and 
duodenal contractions.51
Although erythromycin enjoys the widest use 
of the motilin agonists in the adult population, 
it is not the only agent. Azithromycin use as a 
prokinetic agent has not widely been researched, 
particularly in the pediatric population, but adult 
studies shows promise that azithromycin may 
be an equal alternative to erythromycin and per-
haps some advantages.52 Unlike erythromycin, 
azithromycin is not extensively metabolized by 
CYP3A4, which decreases cardiac risk associated 
with increased blood levels secondary to enzyme 
inhibition.53 Also, although 250 mg of erythromy-
cin and azithromycin induce comparable antral 
activities in adults, higher doses of azithromycin 
have been shown to significantly increase mean 
amplitude and duration of antral activity, sug-
gesting dose-dependent effects.54 Unfortunately, 
the cardiovascular risk from macrolides remains 
and arrhythmia-related effects, including QTc-
interval prolongation, torsades de pointes and 
polymorphic ventricular tachycardia, have been 
observed.55 Azithromycin’s increased duration 
of action, better adverse effect profile, and lack 
of CYP450 interaction indicate that it could be a 
better choice for accelerating gastric emptying 
time; however, more studies of its potential use 
and effectiveness in pediatrics and long-term 
safety in adults need to be conducted.52
Concerns with adverse effects, tachyphy-
laxis with prolonged use, and drug interactions, 
as well as the possibility of resistance, have 
prompted research into novel and specific motilin 
agonists.2 Although there are several agents in 
development, only a few have shown promise. 
In a randomized control trial of 106 patients re-
ceiving doses of 10, 20, 30, and 40 mg, mitemcinal 
accelerated gastric emptying in both diabetic 
and idiopathic gastroparesis, although it was 
especially effective in diabetic gastroparesis.56, 
57 Since the early trials looking at mitemcinal ef-
ficacy, development appears to have stalled, but 
the motilin receptor still remains a good target 
for development of a new agent.
Alternative Contemporary Therapies as Prokinetics
Botulinum toxin A is a purified neurotoxin that 
inhibits the release of acetylcholine into the neu-
romuscular synaptic cleft, with subsequent local-
ized reduction in muscle contractility.58 Pediatric 
data are limited; however, a retrospective study 
has looked at endoscopic, submucosal injection 
of the toxin.59 The study found botulinum toxin 
A to be safe and effective for the treatment of 
intractable pediatric gastroparesis, with older 
age being an independent predictor of response 
to treatment. In the study, botulinum toxin A was 
given at a dose of 6 units/kg, and 30 of 47 partici-
pants reported at least mild improvement, with 
12 of the 30 participants being asymptomatic. The 
median duration of effect from the first injection 
was 3 months in the 30 responders. Of these, 12 
patients required only 1 injection. Of those who 
required subsequent injections, 50% continued 
to respond to repeated injections. Only 1 patient 
reported an adverse reaction with exacerbation 
of vomiting for <1 week.
Baclofen, an antispasmodic and muscle relax-
ant, is yet another agent that may possibly have 
clinical benefit in patients with gastroparesis. 
Although its precise mechanism of action is not 
well understood, it is thought to have an in-
hibitory role on the lower esophageal sphincter 
relaxation through its stimulation of gamma-
aminobutyric acid B (GABA) receptors. In a 
randomized controlled trial of 30 children (2.6-
17.4 years of age) with gastroesophageal reflux 
(GER) refractory to PPIs and H2-antagonists, 
investigators studied the effect of baclofen (0.5 
mg/kg) on transient lower esophageal sphinc-
ter relaxation, GER, and gastric emptying. The 
mean gastric emptying time for the active group 
was 61 minutes compared to 114 minutes for 
the placebo group, showing increased gastric 
emptying with baclofen. Although the trial was 
investigating GER specifically, this nevertheless 
points to efficacy in gastric emptying, if only for 
a particular population.60
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Ghrelin is a close relative of motilin, and it is 
the latest target for drug development treating 
gastric dysmotility. Endogenous ghrelin is a 
hormone that serves multiple functions in the 
body, although of interest to the authors is its 
ability to stimulate the migrating motor complex, 
promote stomach emptying, and augment coor-
dination of contraction between the antral and 
pyloric regions of the stomach.61 Administration 
of exogenous ghrelin has been shown to increase 
gastric emptying both in idiopathic and in dia-
betic gastroparesis.62-64 Use of ghrelin itself, how-
ever, is not practical because of its short half-life 
and poor bioavailability.65 Therefore, synthetic 
ghrelin receptor agonists are in development. 
So far 2 agents have reached clinical trial stage. 
Both TZP-101 and TZP-102 have been shown to 
improve symptoms, although the phase 2b trial 
for TZP-102 had to be stopped early for clinical 
futility.64-67
Another potential target is also a gut hor-
mone. Cholecystekinin (CCK) is excreted from 
duodenal endocrine cells and inhibits gastric 
motility in response to the presence of lipids. 
One would therefore expect that a CCK recep-
tor antagonist would counteract the inhibition 
of gastric motility and promote emptying. In a 
placebo-controlled trial of 6 patients, an infusion 
of loxiglumide, 66 µmol/kg/hr, a CCK antago-
nist, resulted in a mean gastric emptying time 
of 22 minutes compared to 115 minutes for the 
placebo.68 Although this confirms the initial hy-
pothesis, this was a very small trial conducted in 
adults. Better studies, especially in pediatrics, are 
sorely lacking. Ultimately, it is also possible these 
agents will only be useful in gastric dysmotility 
linked with meals of high lipid content.69
Bethanechol is a parasympathomimetic agent 
that is FDA approved for treatment of urinary 
retention. Its activity, however, extends beyond 
the detrusor urinae muscle, as it can also stimu-
late gastric motility, increase gastric tone, and 
often restore impaired rhythmic peristalsis.70 At 
a dosage of 0.25 mg/kg/dose 30 minutes before 
breast feeding, bethanechol resolved gastroin-
testinal symptoms and allowed an increase in 
daily feeding volume in 2 cases of neonatal con-
genital myotonic dystrophy believed to be due 
to maturation arrest of smooth muscle.71 Com-
pared to MCP, however, bethanechol appears 
to be less effective. MCP given at 1 mg/kg was 
compared with 0.075 mg/kg bethanechol and 
placebo for 3 days in 10 infants, and only MCP 
exhibited a statistically significant difference in 
fractional emptying rate and increase in gastric 
fluid output.72
Itopride is a prokinetic benzamide chemically 
related to cisapride and is not approved in the 
United States or United Kingdom. It is a D2 recep-
tor antagonist and anticholinesterase inhibitor, 
both of which lead to the accumulation of acetyl-
choline at cholinergic receptor sites. It is through 
this accumulation that the drug increases the 
lower esophageal sphincter pressure, accelerates 
gastric emptying and improves gastroduodenal 
coordination.73 An open label, multicenter clini-
cal trial in India investigated the combination of 
pantoprazole and itopride in the treatment of 
diabetic gastroparesis over a 3-week period. In 
743 patients in the study, there were statistically 
significant decreases in severity as well as fre-
quency of symptoms such as nausea, vomiting, 
early satiety, bloating, postprandial fullness, 
epigastric pain and regurgitation.74 This suggests 
that itopride may be an alternative agent for the 
treatment of gastroparesis, especially as the risk 
of QTc prolongation appears less compared to 
cisapride. In a randomized, placebo-controlled, 
double-blind, crossover study of 10 young adults 
given 50 mg of itopride 3 times daily, there were 
no statistical differences in the QTc interval at 
baseline and following drug administration.73
Treatment Management of Gastroparesis
Management of gastroparesis starts with 
restoration of fluids and electrolytes, adequate 
nutritional support, and optimization of glyce-
mic control in diabetics. Having small, frequent 
meals throughout the day is a mainstay in ther-
apy to avoid adverse sequelae such as nausea, 
vomiting, and early satiety.1 Another lifestyle 
modification that has shown to improve gastric 
emptying is preprandial physical exercise for 
at least 10 minutes.6 Inserting a gastrostomy or 
jejunostomy tube may be necessary if nutritional 
intake is inadequate. Surgical procedures to as-
sist in improving gastric motility and symptom 
relief include implanting a gastric pacemaker, 
gastric bypass, and partial or complete gastrec-
tomy. These invasive surgical procedures have 
varying degrees of efficacy and may also be 
accompanied by adverse effects such as gastric 
pacemaker dysrhythmias, feeding intolerance, 
and malabsorption.2
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Another component of the management of 
gastroparesis, besides inducing gastric motility, 
is the management of symptoms, particularly 
nausea and vomiting. In fact there are questions 
as to whether the benefit seen with certain proki-
netic drugs such as MCP or DMP is due to their 
antiemetic properties more than their prokinetic 
effects.75 For example, Schade et al11 reported 
that 10 mg of oral MCP acutely enhanced gastric 
emptying in adult patients, but this effect cannot 
be demonstrated after chronic administration, 
even though patients report symptomatic relief. 
As symptomatic relief often does not appear to 
be correlated with gastric emptying, antiemetic 
medications may be useful in symptomatic con-
trol of gastroparesis without having a pharma-
cologic effect on gastric emptying.
The adult guidelines propose a number of 
agents that could serve as adjunctive antiemetic 
therapies with prokinetic drugs such as phe-
nothiazines, antihistamines, 5-HT3-receptor 
antagonists, aprepitant, dronabinol, and tricyclic 
antidepressants.5 Evidence for each is sparse 
and does not appear to be drawn from reports 
studying gastroparesis directly. This holds true 
for pediatric studies as well. One must turn to 
what few data are available in the treatment of 
chemotherapy-induced nausea and vomiting, 
gastroenteritis, or other similar ailments to deter-
mine what agents might be useful. For example, 
a recent Cochrane review of 10 trials examined 
studies of efficacy of dexamethasone, dimenhy-
drinate, granisetron, MCP, and ondansetron in 
acute gastroenteritis in children younger than 18 
years of age. The authors concluded there was 
clear evidence only for ondansetron (0.3 mg/kg) 
as the agent that does the best in aiding cessation 
of vomiting, reducing hospital admissions, and 
reducing the need for intravenous rehydration.76
There are other drugs that could come into 
play during the management of gastroparesis. 
Proton pump inhibitors such as omeprazole, lan-
soprazole, pantoprazole and esomeprazole are 
commonly used in cases of gastrointestinal reflux 
that results as a complication of gastroparesis.77 
Gastroparesis can also manifest with pain that 
requires pharmacological management. No spe-
cific recommendations are made for management 
of pain associated with pediatric gastroparesis, 
although opioids are generally to be avoided 
because of their possible effect in exacerbation 
of gastroparesis.5
CONCLUSIONS
The prognosis for pediatric gastroparesis is 
usually good, but this optimistic outcome is often 
despite current agents that are available for the 
pharmacological management of this condition. 
None of the prokinetic agents currently on the 
market is ideal, particularly for the pediatric 
population. The Table presents a summary of the 
various prokinetic agents used in pediatrics along 
with their evidence for use and limitations. In 
some agents, their efficacy is in question, whereas 
in others, their use is associated with serious 
adverse effects that limit their use; DMP shows 
promising results for relieving gastroparesis in 
pediatrics, but its potential adverse effects caused 
the FDA to limit its use. For those drugs that 
appear to have some efficacy, there are very few 
comparison studies to help guide clinicians as to 
the best agents to use. The trials that are avail-
able are fraught with methodological limitations, 
from small sample sizes to heterogeneity in the 
various populations studied. When it comes to 
pediatrics, what little research is available tends 
to focus on the neonatal population as it relates 
to feeding intolerance or in the management 
of symptoms with antiemetics or other agents; 
therefore, we see most studies try to extrapo-
late medications and dosing from adult clinical 
guidelines for the treatment and management 
of gastroparesis. Unfortunately, medications 
that show promising results in the treatment of 
gastroparesis in adults, do not display equally 
promising results in children.
Although there are new agents are on the hori-
zon, the development is slow going and whether 
they can be what they are promised to be is in 
question based on conflicting results in clinical 
trials. Moving beyond prokinetic medicines, 
there is very little evidence to guide therapy 
choice for antiemetics and analgesics. Current 
evidence reinforces the need for better quality 
studies examining drug therapy for gastropare-
sis. On the one hand, factors that affect response 
to drug therapy and allow us to use current op-
tions better need to be investigated. On the other 
hand, research into newer agents that outperform 
in both efficacy and safety compared to existing 
options needs to continue.
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